Artiva grants director Hougen 16,250 stock options

Artiva Biotherapeutics disclosed a new stock option grant to a director that vests in 2027, adding 16,250 options at a $10.42 exercise price.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that director Elizabeth L. Hougen received a grant of 16,250 director stock options on September 10, 2026. The options have an exercise price of $10.42 per share and expire on September 9, 2036. The award vests in full on the earlier of September 10, 2027, or the company’s 2027 annual stockholder meeting, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 16,250 shares

Grant/Award 1 txn

Insider HOUGEN ELIZABETH L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy) F1	16,250	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 16,250 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

Key Figures

Options granted: 16,250 options Exercise price: $10.42 per share Underlying shares: 16,250 shares +3 more

6 metrics

Options granted 16,250 options Director stock option grant on September 10, 2026

Exercise price $10.42 per share Exercise price of director stock option grant

Underlying shares 16,250 shares Common shares underlying the director stock options

Expiration date September 9, 2036 Option expiration for the director stock option grant

Vesting date Earlier of September 10, 2027, or 2027 annual meeting Full vesting trigger for the 16,250 options

Post-transaction option holdings 16,250 options Director’s direct holdings after reported grant

Key Terms

Director Stock Option (Right to Buy), exercise price, vest in full, annual stockholder meeting

4 terms

Director Stock Option (Right to Buy) financial

"security titled "Director Stock Option (Right to Buy)" was granted"

exercise price financial

"has an exercise price of $10.42 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"shares subject to the option will vest in full on the earlier"

annual stockholder meeting regulatory

"earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting"

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ARTV disclose about Elizabeth L. Hougen’s Form 4 transaction?

ARTV disclosed that director Elizabeth L. Hougen received a grant of 16,250 stock options on September 10, 2026. These options are a compensation-related award, not an open-market purchase or sale of common shares.

What are the key terms of the 16,250 director stock options reported by ARTV?

The award covers 16,250 options to buy Artiva common stock at an exercise price of $10.42 per share. The options are held directly by the director and expire on September 9, 2036 if not exercised earlier.

When do the stock options granted to the ARTV director vest?

The 16,250 options will vest in full on the earlier of September 10, 2027, or the date of Artiva’s 2027 annual stockholder meeting, according to the footnote describing the vesting schedule.

How many ARTV options does the director hold after this Form 4 transaction?

After the reported grant, the director holds 16,250 stock options directly, as stated by the post-transaction holdings figure on the Form 4 for this option award.

Was the ARTV director’s option grant made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and there is no footnote stating that this grant was made pursuant to a Rule 10b5-1 or other pre-arranged trading plan.

What type of security is involved in the ARTV Form 4 filing for the director?

The filing reports a Director Stock Option (Right to Buy), a derivative security that is exercisable into 16,250 shares of Artiva common stock at the stated exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 04:04 PM Accepted by SEC EDGAR 09/14/2026 - 04:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOUGEN ELIZABETH L

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$10.42	09/10/2026		A		16,250		(1)	09/09/2036	Common Stock	16,250	$0	16,250	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

	/s/ Jennifer Bush, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)